91 related articles for article (PubMed ID: 24045316)
1. Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
Grocott R; Metcalfe S; Alexander P; Werner R
N Z Med J; 2013 Jul; 126(1378):60-73. PubMed ID: 24045316
[TBL] [Abstract][Full Text] [Related]
2. PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric.
Grocott R; Metcalfe S
N Z Med J; 2012 Jul; 125(1358):89-90. PubMed ID: 22864151
[No Abstract] [Full Text] [Related]
3. Health economics and health technology assessment: perspectives from Australia and New Zealand.
Streat S; Munn S
Crit Care Clin; 2012 Jan; 28(1):125-33, vii. PubMed ID: 22123104
[TBL] [Abstract][Full Text] [Related]
4. Reimbursement of pharmaceuticals in New Zealand: comments on PHARMAC's processes.
Swinburn B; Milne RJ; Richards M; Begg E; Foote S; Jackson R
N Z Med J; 2000 Oct; 113(1119):425-8. PubMed ID: 11127362
[No Abstract] [Full Text] [Related]
5. [Interpretation of modified prescription for pharmacoeconomic analysis of New Zealand].
Wang X; Su X; Gao Y; Xie Y; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2840-3. PubMed ID: 22292380
[TBL] [Abstract][Full Text] [Related]
6. Insomnia treatment in New Zealand.
O'Keeffe KM; Gander PH; Scott WG; Scott HM
N Z Med J; 2012 Feb; 125(1349):46-59. PubMed ID: 22327158
[TBL] [Abstract][Full Text] [Related]
7. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
8. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. The influence of PHARMAC's National Hospital Pharmaceutical Strategy on Quality Use of Medicines activities in New Zealand hospitals.
Tordoff J; Norris P; Kennedy J; Reith D
N Z Med J; 2006 Aug; 119(1239):U2100. PubMed ID: 16912718
[TBL] [Abstract][Full Text] [Related]
11. PHARMAC and lack of funding for clopidogrel.
White H; Ellis C
N Z Med J; 2005 Jan; 119(1228):U1808. PubMed ID: 16462916
[TBL] [Abstract][Full Text] [Related]
12. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
13. Uptake of new medicines in New Zealand: evidence of a waiting list.
Barber JM; Sheehy KP
N Z Med J; 2015 Apr; 128(1412):10-20. PubMed ID: 25899488
[TBL] [Abstract][Full Text] [Related]
14. The lag from FDA approval to published cost-utility evidence.
Chambers JD; Thorat T; Pyo J; Neumann PJ
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
[TBL] [Abstract][Full Text] [Related]
15. Key informants' perceptions of how pharmac operates in New Zealand.
Ragupathy R; Tordoff J; Norris P; Reith D
Int J Technol Assess Health Care; 2012 Oct; 28(4):367-73. PubMed ID: 23062515
[TBL] [Abstract][Full Text] [Related]
16. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
17. PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate.
Grocott R; Metcalfe S
N Z Med J; 2007 Jul; 120(1258):U2641. PubMed ID: 17653257
[No Abstract] [Full Text] [Related]
18. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders?
MacKay P
N Z Med J; 2005 May; 118(1214):U1433. PubMed ID: 15886729
[No Abstract] [Full Text] [Related]
19. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
Carter D; Vogan A; Haji Ali Afzali H
Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
[TBL] [Abstract][Full Text] [Related]
20. [Cost-utility analysis; uncertainties restrict applicability].
de Neeling JN
Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
